A multivalent approach to the discovery of long-acting beta(2)-adrenoceptor agonists for the treatment of asthma and COPD.

Article Details

Citation

Copy to clipboard

Jacobsen JR, Choi SK, Combs J, Fournier EJ, Klein U, Pfeiffer JW, Thomas GR, Yu C, Moran EJ

A multivalent approach to the discovery of long-acting beta(2)-adrenoceptor agonists for the treatment of asthma and COPD.

Bioorg Med Chem Lett. 2012 Jan 15;22(2):1213-8. doi: 10.1016/j.bmcl.2011.11.072. Epub 2011 Nov 25.

PubMed ID

22178551 [ View in PubMed

]

Abstract

A multivalent approach was applied to the design of long-acting inhaled beta(2)-adrenoceptor agonists. A series of dimeric arylethanolamines based on the short acting beta(2)-adrenoceptor agonist albuterol were prepared, varying the nature and length of the linker between the basic nitrogens. None of the C(2)-symmetric dimers demonstrated increased potency, however dimer 5j, derived from 4-phenethylamine, was found to have increased binding potency in vitro relative to the parent monomer. Optimization of this structure led to the identification of 22 (milveterol) which demonstrates high potency in vitro and long duration of action in a guinea pig model of bronchoprotection.

DrugBank Data that Cites this Article

Binding Properties

Drug	Target	Property	Measurement	pH	Temperature (°C)
Salmeterol	Beta-1 adrenergic receptor	EC 50 (nM)	251.19	N/A	N/A	Details